PMID

Data

Article Title

Organization

Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.

Arena Pharmaceuticals

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP

Novartis Institutes For Biomedical Research

Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.

Askat

Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists [corrected].

Roche Palo Alto

Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH

Jagiellonian University Medical College

The therapeutic journey of pyridazinone.

Jamia Hamdard

Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.

Ono Pharmaceutical

Discovery of G Protein-Biased EP2 Receptor Agonists.

Ono Pharmaceutical

Piperidine derivatives as nonprostanoid IP receptor agonists 2.

Toray Industries

Piperidine derivatives as nonprostanoid IP receptor agonists.

Toray Industries

Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists.

Ono Pharmaceutical

Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.

Jagiellonian University Medical College

Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat.

Arena Pharmaceuticals

A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.

Amgen

Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.

Merck Research Laboratories

Prostanoid receptor EP2 as a therapeutic target.

Emory University

Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.

Novartis Institutes For Biomedical Research

Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.

Institute Of Organic Synthesis

Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.

Universit£

Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.

Merck Frosst Canada

Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.

Merck Frosst Centre For Therapeutic Research

Comparison between two classes of selective EP(3) antagonists and their biological activities.

Merck Frosst Centre For Therapeutic Research

Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2.

Fujisawa Pharmaceutical

Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.

Fujisawa Pharmaceutical

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.

Merck Frosst Centre For Therapeutic Research

Discovery of new orally active prostaglandin D2 receptor antagonists.

Ono Pharmaceutical

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.

Amira Pharmaceuticals

Design and synthesis of new prostaglandin D2 receptor antagonists.

Minase Research Institute

Discovery of selective indole-based prostaglandin D2 receptor antagonist.

Minase Research Institute

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.

Amira Pharmaceuticals

The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid.

Merck Frosst Centre For Therapeutic Research

Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.

Merck Frosst Centre For Therapeutic Research

Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.

Merck Frosst Canada

1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists.

Decode Chemistry

Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists.

Decode Chemistry

The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.

Merck Frosst Centre For Therapeutic Research

Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that

Decode Chemistry

Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.

Amira Pharmaceuticals

Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.

Glaxosmithkline

 

Molecular design of novel PGI₂ agonists without PG skeleton. IV

TBA

 

Molecular design of novel PGI₂ agonists without PG skeleton. III

TBA

 

Molecular design of novel PGI₂ agonists without PG skeleton. II

TBA

 

Molecular design of novel PGI₂ agonists without PG skeleton. I

TBA

Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.

Glaxosmithkline

Discovery of potent and selective DP1 receptor antagonists in the azaindole series.

Merck Frosst Centre For Therapeutic Research

3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists.

Decode Chemistry

Highly functionalized 7-azaindoles as selective PPAR gamma modulators.

Merck Research Laboratories

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

Merck Frosst Canada

Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6.

Fujisawa Pharmaceutical

Identification of an indole series of prostaglandin D2 receptor antagonists.

Merck Frosst Canada

Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.

Toray Industries

Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.

Fujisawa Pharmaceutical

Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.

Fujisawa Pharmaceutical

A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic.

Fujisawa Pharmaceutical

Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.

Merck Frosst Centre For Therapeutic Research

Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.

Merck Frosst Centre For Therapeutic Research

Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.

Procter & Gamble Pharmaceuticals

Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.

Minase Research Institute

Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.

Minase Research Institute

Design and synthesis of a highly selective EP2-receptor agonist.

Minase Research Institute

Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.

Merck Frosst Canada

A novel pyridazinone derivative as a nonprostanoid PGI2 agonist.

Fujisawa Pharmaceutical

Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.

Procter And Gamble Pharmaceuticals

New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.

Merck Frosst Centre For Therapeutic Research

Bicyclo[2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane derivatives: orally active, potent, and selective prostaglandin D2 receptor antagonists.

Shionogi

Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic.

Bristol-Myers Squibb Pharmaceutical Research Institute